O
0.074
0.00 (6.62%)
| Previous Close | 0.070 |
| Open | 0.066 |
| Volume | 11,054,435 |
| Avg. Volume (3M) | 22,494,400 |
| Market Cap | 3,286,957 |
| Price / Sales | 0.030 |
| Price / Book | 0.030 |
| 52 Weeks Range | |
| Earnings Date | 12 Jun 2025 - 16 Jun 2025 |
| Operating Margin (TTM) | -650.31% |
| Diluted EPS (TTM) | -87.25 |
| Total Debt/Equity (MRQ) | 24.67% |
| Current Ratio (MRQ) | 0.060 |
| Operating Cash Flow (TTM) | -13.89 M |
| Levered Free Cash Flow (TTM) | -4.14 M |
| Return on Assets (TTM) | -19.14% |
| Return on Equity (TTM) | -201.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Onconetix, Inc. | - | - |
AIStockmoo Score
-0.5
| Analyst Consensus | -2.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -0.5 |
| Average | -0.50 |
|
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men’s health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 35.43% |
| % Held by Institutions | 2.80% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Scientech Research Llc | 31 Mar 2025 | 29,853 |
| Fifth Third Bancorp | 31 Mar 2025 | 2,404 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 11 Jun 2025 | Announcement | Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |